Log In
BCIQ
Print this Print this
 

Actair, House dust mites sublingual immunotherapy tablet (S-524101)

  Manage Alerts
Collapse Summary General Information
Company Stallergenes Greer plc
DescriptionSublingual desensitization tablet to house dust mite allergies
Molecular Target
Mechanism of ActionImmunotherapy
Therapeutic Modality 
Latest Stage of DevelopmentApproved
Standard IndicationAllergy
Indication DetailsTreat house dust mite allergic rhinitis
Regulatory Designation Japan - Standard Review (Treat house dust mite allergic rhinitis)
PartnerShionogi & Co. Ltd.

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

1

0

$31.0M

$59.3M


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone

09/13/2010

Undisclosed

$31.0M

$59.3M

Get a free BioCentury trial today